Literature DB >> 23948350

Icotinib: kick-starting the Chinese anticancer drug industry.

D Ross Camidge1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23948350     DOI： 10.1016/S1470-2045(13)70385-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.

Authors:  Pei Hu; Jia Chen; Dongyang Liu; Xin Zheng; Qian Zhao; Ji Jiang
Journal:  Eur J Clin Pharmacol       Date:  2015-05-21       Impact factor: 2.953

Review 2.  Medical management of lung cancer: Experience in China.

Authors:  Yuankai Shi; Yan Sun
Journal:  Thorac Cancer       Date:  2015-01-07       Impact factor: 3.500

3.  Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells.

Authors:  Xuanxuan Wang; Yanjun Gu; Hai Liu; Liming Shi; Xiaonan Sun
Journal:  Onco Targets Ther       Date:  2018-03-05       Impact factor: 4.147

4.  The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.

Authors:  Qiaofeng Zhong; Yunxia Tao; Haizhu Chen; Yu Zhou; Liling Huang; Xiaohong Han; Yuankai Shi
Journal:  Lancet Reg Health West Pac       Date:  2021-04-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.